Leesar Inc., Fort Myers, FL
Is Leesar Inc. registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Leesar Inc. in Fort Myers, FL, first registered Apr 30, 2014 and most recently registered Nov 26, 2025.
Does Leesar Inc. hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 5 licenses for this name and city, as of Nov 15, 2026: PH26058 for LEESAR INC, FORT MYERS, status Clear, PH27705 for LEESAR, INC, FT MYERS, status Clear, PH31810 for LEESAR INC. (dba SOUTHWEST FLORIDA PHARMACEUTICAL REPACK), FT MYERS, status Clear and PH32477 for LEESAR INC (dba LEESAR), FORT MYERS, status Clear, and 1 more listed below.
Has Leesar Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Feb 18, 2020) and 2 untitled letters (Jun 17, 2022 and Nov 21, 2025) for Leesar Inc. State board actions: no Florida Board of Pharmacy action on licenses PH26058, PH27705, PH31810 and PH32477 and the others below or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Leesar Inc.; LeeSar, Inc.
- Location
- Fort Myers, FL
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as Leesar Inc.
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Nov 21, 2025
- FDA Data Dashboard inspections
- 5 inspections: 1 OAI, 4 VAI; 5 published Form 483s
- Form 483 text on this page
- 4 Form 483s, 23 observations
- State board records
- License found: PH26058, Clear; PH27705, Clear; PH31810, Clear; PH32477, Clear; PH36530, Clear
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as LeeSar, Inc., a 503B facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Nov 21, 2025 | Untitled letter | Untitled Letter issued 11/21/2025 | fda.gov |
| May 9, 2025 | Form 483 | 483 Issued 05/09/2025 | fda.gov |
| Jun 17, 2022 | Untitled letter | Untitled Letter Issued 06/17/2022 | FDA copy (archived) |
| Oct 29, 2021 | Form 483 | 483 Issued 10/29/2021 | FDA copy (archived) |
| Feb 18, 2020 | Warning letter | Warning Letter (02/18/2020) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists LEESAR, INC, Fort Myers, FL (FEI number 3010166880), matched to this page by exact name, city and state. It lists 5 inspections: 1 OAI, 4 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jul 18, 2025 | Voluntary Action Indicated (VAI) | Compliance: Devices (Devices): Voluntary Action Indicated (VAI); Postmarket Assurance: Devices (Devices): No Action Indicated (NAI) | 3010166880 | 1276435 |
| May 9, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010166880 | 1269588 |
| Oct 29, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010166880 | 1155647 |
| Jul 12, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010166880 | 1017863 |
| Aug 8, 2014 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010166880 | 893985 |
Form 483s FDA has published for this site
- Sep 23, 2026: Form 483 to LEESAR, INC, published Nov 5, 2026. fda.gov
- May 9, 2025: Form 483 to LEESAR, INC, published Jun 23, 2025. fda.gov
- Oct 29, 2021: Form 483 to LEESAR, INC, published Mar 16, 2022. fda.gov
- Oct 24, 2018: Form 483 to LEESAR, INC, published Jan 17, 2024. fda.gov
- Jan 16, 2018: Form 483 to LEESAR, INC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 23 numbered observations in all, across 4 inspections ending Jul 12, 2017 to Sep 23, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection dated Sep 23, 2026 by FDA (dates on the form not read): 9 observations
- Firm on the cover
- LEESAR, INC., 2727 Winkier Avenue, Fort Myers, Florida 33901
- FEI number
- 3010166880
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- Florida District Office 555 Winderley Place Suite 200 Maitland, FL 32571
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
:
Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, you failed to properly maintain the equipment inside the ISO 5 classified areas of your <Redacted B4> Compounding Systems. During the inspection of the <Redacted B4> systems located in <Redacted B4> Room Suite <Redacted B4> Room Number <Redacted B4> the following conditions were observed:
1. On 09/09/2026, what appeared to be rust and chipping paint was observed at the fixed base of the <Redacted B4> inside the ISO 5 classified area of <Redacted B4>, and at the junction between the fixed base and rotating section of the <Redacted B4>. In addition, on 09/10/2026, a reddish-colored seal at the base of the <Redacted B4> appeared to have been coated with paint after the base was repainted.
2. On 09/09/2026, what appeared to be extensive rust and chipping paint was observed at the fixed base of the <Redacted B4> inside the ISO 5 classified area of <Redacted B4>, including significant deterioration and corrosion at the junction where the <Redacted B4>. ...
Observation 2
:
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.
Specifically, your firm's environmental monitoring (EM) program does not adequately address the identification, evaluation and corrective actions that should be taken for microorganisms recovered in your facility. For example,
A. As per SOP 6.22 rev 04 Environmental Monitoring Program, you have established microbial contamination alert and action limits for air and surface sampling performed in your classified areas and personnel monitoring that are not appropriate for ISO 5 classified areas. Surface sample alert <Redacted B4> CFU) and action <Redacted B4> CFU) levels permit recovery of microorganisms in critical ISO 5 areas, including the <Redacted B4> containment cells and vestibules, without warranting a formal investigation, corrective action, or preventive measure. Samples from ISO 5 environments should yield no microbiological contaminants, and any recovery in these critical areas should prompt a formal investigation and corrective action.
B. ...
Observation 3
:
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically,
A. Your firm's Quality Unit (QU) failed to exercise adequate oversight and did not implement appropriate corrective and preventive actions in response to microbial contamination recovered within the <Redacted B4> ISO 5 containment cell. On 10/25/2025, surface sample <Redacted B4> from <Redacted B4> yielded 1 CFU identified as Serratia marcescens, a gram-negative opportunistic pathogen with known clinical significance. This recovery was documented under deviation UDR 2025-10 and classified as an out-of-trend (OOT) statistical outlier, within established EM alert and action limits. The QU classified this event as major yet assessed the risk as minimal. ...
Observation 4
:
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Specifically, your firm has established the Beyond-Use-Dates for repackaging finished drug product Dexmedetomidine HCI 20 mcg/5 mL into 10mL syringes based on assay specifications outside the defined manufacturer's specifications. Your firm has assigned BUDs of <Redacted B4> days at Controlled Room Temperature (CRT) andE} days under refrigerated conditions for this repackaged product but do not have data to support these timeframes. For example, the following technical study lots failed potency testing as per the manufacturer's specifications:
• Room temperature Lot <Redacted B4> compounded 02/08/2026, reported assay result of 89.7% on Day <Redacted B4> b)(4) • Room temperature Lot <Redacted B4> compounded 02/09/2026, reported assay result of 92.6% on Day <Redacted B4> • Refrigerated Lot <Redacted B4>, compounded 04/15/2026, reported assay result of 93.4.% on Day <Redacted B4> • Refrigerated Lot: <Redacted B4> compounded 04/16/2026, reported assay result of 88.4% on Day <Redacted B4> ______ ...
Observation 5
:
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity. Specifically,
A. Your firm established a pH specification of <Redacted B4> as of 08/19/2022 for finished compounded drug product Azithromycin 500mg in a 250mL Dextrose 5% IV Bag but expanded the specification to <Redacted B4> on 12/03/2025 without adequate scientific justification or any supporting data.
B. Your firm is not using the finished drug manufacturer's defined assay specifications for repackaged -Dexmedetomidine HCl 20 mcg/5 mL syringes and applies a wider acceptance criteria without adequate scientific justification. The finished drug manufacturer's Certificate of Analysis (COA) specifies an assay acceptance criterion of <Redacted B4> of label claim; however, your firm applies an acceptance criterion of <Redacted B4>. As a result of this unjustified wider specification, Dexmedetomidine HCI 20 mcg/5 mL syringes have been released with potency results outside the manufacturer's specifications. ...
Observation 6
:
The accuracy, sensitivity, specificity, reproducibility of test methods have not been established and documented.
Specifically,
A. The assay method used to test the repackaged drug product Dexmedetomidine HCL 20 mcg/5 mL has not been validated. Documentation, QUF-414-VJ Certificate of Analysis dated 08/07/2026, obtained from your contract testing laboratory indicates that the potency method used met system suitability requirements under a non-cGMP analysis protocol, and that product-specific method validation was not performed for the sample. The contract laboratory further noted that the reported specifications were provided for informational purposes only, and that your firm bears responsibility for verifying that the specification and analyzed reported are appropriate for the product being tested. Your firm was unable to provide any evidence demonstrating that the method used to test this product has been appropriately validated.
B. Your firm outsources your finished drug product sterility testing to a third-party laboratory who performs an ATP-bioluminescent method. ...
Observation 7
:
Written procedures are not established or followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically,
A. You, <Redacted B4> cleaning procedures are deficient since they fail to define the use of a sporicidal agent to clean and disinfect the ISO 5 vestibule areas of your <Redacted B4> Compounding Systems which operators use to clean components, containers and closures prior to loading them into each <Redacted B4> System. Your cleaning procedure only includes a cleaning log which states'~ the vestibules with <Redacted B4>. Your procedure does not require operators to use a sporicidal cleaning agent as part of your cleaning process for the ISO 5 vestibules. During environmental monitoring activities on 05/15/2026, you recovered the endospore-forming microorganism Bacillus spp in the ISO 5 <Redacted B4> vestibule and the ISO 5 <Redacted B4> vestibule. Your procedures do not require the use of sporicidal agents to ensure the ISO 5 vestibules are free from endospore-forming microorganisms.
B. ...
Observation 8
:
The persons double-checking the cleaning and maintenance are not dating, signing or initialing the equipment cleaning and use log.
SpecificaJly, you failed to verify that the cleaning operations for you <Redacted B4> and <Redacted B4> cleanrooms were performed at the time cleaning operations were conducted. Your Good Documentation Practices procedure requires critical steps or operations to be verified by a second person, and for the second person to sign/initial and date when the operation is performed indicating the second person observed/witnessed the entire step or operation. Your <Redacted B4> cleaning records, and <Redacted B4> Room cleaning records require operators who perform cleaning operations to complete, sign/initial and date each form. The forms also require QA to verify each cleaning operation was performed by also signing/initialing and dating each form. Multiple instances were observed on your cleaning records where the QA verifier initialed and dated the cleaning records days after the cleaning operations were performed. The QA verifier failed to initial and date the forms at the time cleaning operations were conducted. For example, ...
Observation 9
:
Samples of representative units were not visually examined for correct labeling at the completion of finishing operations.
Specifically, you failed to visually inspect representative samples of your finished drug products to ensure they contain the correct labeling. Your Visual Inspection Program requires 100% visual inspection of your syringe and IV bag drug products for defects such as leaks, particles, metal, fiber and hair. Inspectors document the results of their inspection on Visual Inspection Worksheets which are included with each product's batch manufacturing record. Your procedure does not require inspectors to perform a visual inspection of finished drug products for the correct labeling. Your Visual Inspection Worksheets also do not show finished product labeling is visually examined, including the worksheets for Heparin Sodium 500U into 500mL 0.9% NaCl IV Bags, Lot# HEPA500020260824, and Phenylephrine HCL 40mg into 250ml 0.9% NaCl IV Bags, Lot #s PHEN4020260824, PHEN4020260825 and PHEN4020260826.
Inspection Apr 29, 2025 to May 9, 2025: 4 observations
- Firm on the cover
- LEESAR, INC, 2727 Winkler Ave, Fort Myers, FL 33901-9358
- FEI number
- 3010166880
- Establishment type on the cover
- 503B Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Your firm failed to fully investigate an out of specification pH test result for Azithromycin 500mg in a 250mL Dextrose 5% IV Bag campaign comprised lot# <Redacted B4> and<Redacted B4> prior to release and distribution. On 04/22/2025, your contract laboratory reported the pH result at 7.2, outside your established specification range of <Redacted B4>. Your quality unit opened investigation UDR2025-02 on 04/22/2025 and reported this failure as a major deviation in the risk assessment. The contract laboratory retested this product on 04/25/2025 and reported a passing pH result at 7.0 under a different specification range on <Redacted B4>. This change to the specification was discovered during the inspection and presented to your quality unit who was unaware of the change. Your firm reported this specification range was inadvertently changed by the contract laboratory. ...
Observation 2
The responsibilities and procedures applicable to the quality control unit are not in writing and folly followed.
Specifically,
A. Your quality unit is not following written procedure 6-8 rev 03 Quality Events and Investigations Management Process dated November 16, 2021, that defines how deviations are handled and investigated at your firm. This procedure describes how you classify deviations as minor, major and critical based on the possible process impact and product quality. The subsequent investigation is then conducted based on that classification. The following examples are deviations where the quality unit failed to properly classify the deviation as per your written procedure:
i. UDR 2024-07 dated December 02, 2024, is the investigation for the OOS repo1ted air samples taken on November 26, 2024, in the ISO 7 compounding areas that was classified as minor in the risk assessment. This deviation as per your procedure should be categorized as a major deviation.
ii. ...
Observation 3
Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
Specifically, your firm does not maintain written records for annual product reviews conducted for your aseptically produced drug products including but not limited to:
Amiodarone 900mg added to Dextrose 5% 500mL bag
Azithromycin 500mg added to Dextrose 5% 250mL bag
Diltiazem 125mg added to Dextrose l 00mL bag
Hepruin S000U added to 0.9% NACL 500mL bag
Hepruin I0000U added to 0.9% NACL 500mL bag
Hydromorphone 50mg added to 0.9% NACL 250mL bag
Lidocaine 2% (60mg/mL) 2mL repacked in 3mL syringe
Norepinephrine 8mg added to 0.9% NACL 500mL bag
Oxytocin 30U added to 0.9% NACL 500mL bag
Phenylephrine 40mg added to 0.9% NACL 250mL bag
Phenylephrine 100mcg/mL in 10mL syringe
Succinykholine 20mg/mL repacked in 110mL syringe
Vancomycin 1.25g added to 0.9% NACL 250mL bag
Vancomycin 1.5g added to 0.9% NACL 250mL bag
Observation 4
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically, your firm does not have a change control program or written procedure to define and describe how your firm will properly document and evaluate changes within your processes including but not limited to changes within your manufacturing operations, product specifications or standard operating procedures/programs. For example, on 08/19/2022 the finished product pH specifications for Azithromycin 500mg added to Dextrose 5% 2 50ml bag were changed from <Redacted B4> the <Redacted B4> but there is no change control documentation describing the justification and implementation of this change.
Inspection Oct 18, 2021 to Oct 29, 2021: 5 observations
- Firm on the cover
- LEESAR, INC, 2727 Winkler Ave, Fort Myers, FL 33901-9358
- FEI number
- 3010166880
- Establishment type on the cover
- 503B outsourcing facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically,
A. Your firm failed to fully investigate an out of specification potency test result for Vancomycin 1.5g Lot <Redacted B4>. On 10/26/2020, your contract laboratory reported a result of 89.4%, outside the specifications of <Redacted B4>%. You reported this failure as a major deviation in the risk assessment. The quality unit approved this product for release on 10/28/2020 without proper justification to the investigation and there was no additional follow up with any associated batches. This batch was distributed on 10/29/2020 and 10/30/2020.
B. Your firm failed to identify and investigate an OOS potency test result for Vancomycin 1.25g Lot <Redacted B4> with a result of 89.8% on 09/08/2020 (specification <Redacted B4> % and the product was approved for release by the quality unit on 09/08/2020 and on 09/18/2020. There was no investigation opened for this OOS result.
C. Your firm failed to investigate failures of the compounding batch yields. The specification for intermediate batch yield is greater than or equal to 1 % yield. ...
Observation 2
Written procedures are not established that describe the tests to be conducted on appropriate samples of in-process materials of each batch.
Specifically, you have not validated the process(es), or equivalent, to demonstrate that the automated system could consistently compound IV bags and syringes within specification for potency over multiple lots and days.
Observation 3
The master production and control records are deficient in that they do not include a statement of theoretical yield and yield percentages.
Specifically,
A. There are no calculations of final batch yield listed in master batch records. An intermediate batch yield is calculated prior to visual inspection. Once product is released or rejected from visual inspection there are no numbers reported in the batch record to include the final batch quantity and the number of rejected products to establish a final yield of finished products.
B. Calculations used to determine the passing of visual inspection training are not inclusive of the actual number of correctly identified units. Specifically, false positive units are not accounted in current calculation; thus, affecting percent calculations and pass/fail status of training. Recalculation, with the consideration of false positives, revealed that operator <Redacted B4> does not meet the passing criterion; however, this operator is performing routine visual inspection on current batches of product.
Calculations used to determine the passing of visual inspection training are not inclusive of the actual number of correctly identified units. ...
Observation 4
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Specifically, the following product was compounded and not identified on your report dated June 2021.
• Calcium Gluconate 1 gm
Observation 5
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(IO)(A). Specifically, the following information is not found on your drug product labels:
a) The dosage form and strength
b) A list of active and inactive ingredients identified by established name and the quantity or proportion of each ingredient. Examples of your drug product labels that do not contain this information:
• Azithromycin 500 mg added to Dextrose 5% 250 mL (2 mg/mL)
• Diltiazem 125 mg added to Dextrose 5% 100 mL (1 mg/mL)
• Heparin 5,000 units added to NaCl 0.9% 500 mL (10 units/mL)
• Heparin 10,000 units added to NaCl 0.9% 1000 mL (10 units/mL)
• Hydromorphone 50 mg added to NaCl 0.9% 250 mL (0.2 mg/mL)
• Oxytocin 30 units added to NaCl 0.9% 500 mL (0.06 units/mL)
• Phenylephrine 40 mg added to NaCl 0.9% 250 mL (160 mcg/mL)
• Phenylephrine 1 mg/10 mL in 10 mL syringe (100 mcg/mL)
• Succinylcholine 120 mg/6 mL in 10 mL syringe (20 mg/mL)
• Succinylcholine I 00 mg/5 mL in 10 mL syringe (20 mg/mL)
• Vancomycin 1.25 g added to NaCl 0.9% 250 mL (5 mg/mL)
• Vancomycin 1.5 gadded to 0.9% NaCl bag 250 mL (6 mg/mL)
Inspection Jul 3, 2017 to Jul 12, 2017: 5 observations
- Firm on the cover
- LEESAR, INC, 2727 Winkler Ave, Fort Myers, FL 33901-9358
- FEI number
- 3010166880
- Establishment type on the cover
- Out sourcing Facility
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217- 2597
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically, the firm uses non-sterile cleaning agents for all REDACTED (b)(4) (ISO 5) REDACTED (b)(4) Room (ISO 7), and REDACTED (b)(4) Room (ISO 8) on a routine basis.
Observation 2
Procedures designed to prevent microbiological contamination of chu g products pmpo1ting to be sterile are not followed.
Specifically, on 07/03/2017, we observed your pharmacy technicians gathering dru g components and supplies, located outside the ISO 5 area, without changing or sanitizing their gloved hands REDACTED (b) (4) times while loading and unloadin g your firm 's REDACTED (b)(4) (regulated as a Class II medi ca l dev ice by FDA) REDACTED (b)(4) systems that maintain ISO-5 environments.
Observation 3
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.
Specifically,
1. Your firm failed to open investigations for 3,855 rejections in 2016 and 2,278 rejections in 2017 by your firm's REDACTED (b)(4) injectable drug compounding systems.
a. Your firm relies on the REDACTED (b) (4) compounding system's internal weigh ba lance to perform an accurate REDACTED (b) (4) to achi eve the intended concentration.
i. In 2016: 2,286 rejections occuned for weight enors or invalid dosing volume, resulting in 59.30% of all rejections.
11. In 2017: 1,511 rejections occuned for weight enors or invalid dosing volume, resulting in 66.33% of all rejections.
2. Your firm failed to adequately investigate 3 related complaints for mislabeled product that was released by your quality unit.
a. On 12/21/2015, your firm received a complaint regarding twenty-four (24) Vancomycin
bags labeled with two different strengths of Vancomycin on the same bag. b. On 03/22/2016, your firm received a complaint regarding one (1) Vancomycin bag
labeled with two different strengths of Vancomycin on the same bag. c. ...
Observation 4
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
***THIS IS A REPEAT OBSERVATION***
Specifically,
1. Airflow studies performed under dynamic conditions did not follow the vendor's written
protocol. 2. The airflow studies performed since the last FDA inspection were deficient in determining if the processing equipment does not alter or impede the unidirectional cascade of air from the HEPA f ilters to the ISO 5 classified area where sterile diug products are manipulated. 3. Room certiifications conducted for 2015 and 2016 did not account for the increase from (b) (4) p ersonnel performing aseptic operations in the ISO 7 area.
Observation 5
The establishment of laborato1y control mechanisms including any changes thereto, are not reviewed and approved by the quality control unit.
Specifically, your firm's visual inspection process is deficient.
1. On 07/03/17, we observed your quality assurance personnel REDACTED (b)(4) Hydromorphone 50mg added to 0.9% NaCl Bag 250 mL, Lo t HYDR0-2 3-JUN-17, during the visual inspection process. 2. Thirty-four (34) mislabeled products, from 3 separate lots, failed to be detected by your firm's visual inspection process.
3. The visual inspection of finished products for part iculate matter is not conducted against a
contrasting background or adequate lighting to optimize the viewing conditions. 4. Labels affixed to your final product limit the visual inspection process.
Linked 483s whose text is not shown
- Jan 16, 2018: FDA document 89196: the PDF is a scanned image with no readable text.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH26058 | Pharmacy | LEESAR INC | FORT MYERS | Clear |
| PH27705 | Pharmacy | LEESAR, INC | FT MYERS | Clear |
| PH31810 | Pharmacy | LEESAR INC. (dba SOUTHWEST FLORIDA PHARMACEUTICAL REPACK) | FT MYERS | Clear |
| PH32477 | Pharmacy | LEESAR INC (dba LEESAR) | FORT MYERS | Clear |
| PH36530 | Pharmacy | LeeSar, Inc (dba LeeSar Physician Central Fill) | FORT MYERS | Clear |
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
FDA’s 503B list
- Leesar Inc., Fort Myers, FL: last inspection Sep 28, 2026, Form 483 at that inspection: Yes, action FDA lists: Open.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.